An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Trial Profile

An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs PRX 106 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 May 2017 According to a Protalix BioTherapeutics media release, the company expects full results from this trial around the end of 2017..
    • 05 Dec 2016 According to a Protalix BioTherapeutics media release, the company will announce data from this study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top